Article
Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder.
The pharmacogenomics journal - 1 Aug 2021
Zastrozhin M S, Skryabin V Yu, Petukhov A E, Torrado M V, Pankratenko E P, Zastrozhina A K, Grishina E A, Ryzhikova K A, Shipitsyn V V, Bryun E A, Sychev D A
Abstract excerpt
Citalopram is commonly prescribed to patients suffering from major depressive disorder. Some of them do not respond adequately to therapy with citalopram, while many of them experience type A adverse drug reactions. Current research revealed that CYP2C19 isoenzyme is involved in the biotransformation of citalopram. The objective of our study was to investigate the impact of 681G>A polymorphism of the CYP2C19 gene...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.